Since we used artificial probes in this study, the next step will be to validate this approach by detecting EGFR gene deletions or mutations in cell extracts and in plasma from patients with EGFR-mutated tumors, such as NSCLC, a feature that is unique to the μLAS system and cannot be replicated by conventional amplification strategies. This evidence concerns the gene EGFR and non-small cell lung carcinoma.